|Bid||2.0400 x 800|
|Ask||2.0800 x 800|
|Day's Range||2.0300 - 2.1100|
|52 Week Range||1.2900 - 5.5700|
|Beta (3Y Monthly)||1.13|
|PE Ratio (TTM)||N/A|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||N/A|
CHARLESTON, S.C., Aug. 20, 2019 -- Aeterna Zentaris Inc. (NASDAQ: AEZS) (TSX: AEZS) today announced that Jonathan Pollack has resigned as a director of the Company for personal.
CHARLESTON, S.C., Aug. 13, 2019 -- Aeterna Zentaris Inc. (NASDAQ: AEZS) (TSX: AEZS) today reported its financial and operating results for the second quarter ended June 30,.
Aeterna Zentaris Inc. (AEZS) (AEZS) today announced that it is reducing the size of its German workforce and operations to more closely reflect the Company's ongoing commercial activities in Frankfurt. The Company is also providing an update on the previously disclosed securities class action lawsuit pending in the U.S. District Court for the District of New Jersey, brought on behalf of shareholders of the Company. The lawsuit alleges violations of the Securities Exchange Act of 1934 in connection with allegedly false and misleading statements made by the defendants between August 30, 2011 and November 6, 2014 regarding the safety and efficacy of Macrilen™ (macimorelin) and the prospects for the approval of the Company's New Drug Application for the product by the FDA.
CHARLESTON, S.C., May 08, 2019 -- Aeterna Zentaris Inc. (NASDAQ: AEZS) (TSX: AEZS) announced today at its annual and special shareholders’ meeting held on May 8, 2019, that the.
CHARLESTON, S.C., May 07, 2019 -- Aeterna Zentaris Inc. (NASDAQ: AEZS) (TSX: AEZS) today reported its financial and operating results for the first quarter ended March 31,.
Aeterna Zentaris Inc. (AEZS) (AEZS) today reported its financial and operating results for the fourth quarter and year ended December 31, 2018. The increase in total revenue in 2018 relates to license fees, royalty income and product sales associated with executing the License and Assignment Agreement for Macrilen™ (macimorelin) in January 2018.
Aeterna Zentaris Inc. (AEZS) (AEZS) will announce its fourth quarter and year ended December 31, 2018 financial and operating results after market close on Tuesday, March 26, 2019. Aeterna Zentaris Inc. is a specialty biopharmaceutical company focused on commercializing novel pharmaceutical therapies, principally through out-licensing arrangements. Aeterna Zentaris is a party to a license and assignment agreement with a subsidiary of Novo Nordisk A/S to carry out development, manufacturing, registration and commercialization of Macrilen™ (macimorelin) in the United States and Canada.
Aeterna Zentaris Inc. (AEZS) (AEZS) announced today that its board of directors has formed a special committee of independent directors (the “Special Committee”) to review strategic options available to Aeterna Zentaris. The Special Committee has approved the engagement by the Company of Torreya, a global investment bank specializing in life sciences, as its financial advisor. Torreya is working with management to assist the Special Committee and the board of directors in considering a wide range of transactions (including opportunities for the license of macimorelin outside of the United States and Canada, other monetization transactions relating to macimorelin or the potential sale of the company) which may create value for the company, its shareholders and other stakeholders.
Aeterna Zentaris Inc. (AEZS) (AEZS) announced that the European Medicines Agency (EMA) has granted marketing authorization for macimorelin, an orally available ghrelin agonist, for diagnosis of adult growth hormone deficiency (AGHD). “Clinical studies have demonstrated that macimorelin is safer and much simpler to administer than the current methods of testing for insulin-induced hypoglycemia, and is well-tolerated by patients and reliable in diagnosing the condition,” said Dr. Christian Strasburger, the Head of Clinical Endocrinology at Charité Unversitaetsmedizin Berlin and the principal investigator for macimorelin. AGHD may occur in an adult subject who has a history of childhood onset growth hormone deficiency (GHD) or may occur during adulthood as an acquired condition.
CHARLESTON, S.C., Dec. 21, 2018 -- Aeterna Zentaris Inc., (NASDAQ:AEZS) (TSX: AEZS) has settled its previously disclosed litigation in South Carolina and Canada with former.
CORAL GABLES, FL / ACCESSWIRE / November 19, 2018 / Healthcare stocks have rallied during the last 3 trading sessions. On Friday, the market powered higher, lead by healthcare stocks. Furthermore, the idea that a split congress could be a good thing for healthcare stocks is offering a brighter outlook for some investors to look closer at several smaller healthcare companies that could be set to rebound.
Aeterna Zentaris Inc. (AEZS) (AEZS), announced the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has adopted a positive opinion recommending a marketing authorization for macimorelin, an orally available ghrelin agonist, for diagnosis of adult growth hormone deficiency (AGHD). The recommendation will now be reviewed by the European Commission. “We are pleased with the CHMP’s positive opinion of macimorelin for AGHD,” said Michael V. Ward, Chief Executive Officer of Aeterna Zentaris.
CORAL GABLES, FL / ACCESSWIRE / November 16,2018 / There's no denying the progress that the healthcare industry has made. According to analyst firm Market Research Engine, the E-Health Market is expected to exceed more than US$136 Billion by 2024 at a CAGR of 21% in the given forecast period. Bank of America surveyed** 225 fund managers with $641 billion in assets under management, who said the most "crowded trade" is in tech stocks.
NEW YORK, Nov. 16, 2018 -- In new independent research reports released early this morning, Fundamental Markets released its latest key findings for all current investors,.
CHARLESTON, S.C., Nov. 06, 2018 -- Aeterna Zentaris Inc. (NASDAQ: AEZS) (TSX: AEZS), a biopharmaceutical company engaged in developing and commercializing pharmaceutical.
CHARLESTON, S.C., Nov. 06, 2018 -- Aeterna Zentaris Inc. (NASDAQ:AEZS) (TSX: AEZS) and Cogas Consulting, LLC have amicably resolved their dispute with Aeterna Zentaris Inc..
NEW YORK, NY / ACCESSWIRE / November 1, 2018 / Traders News Source, a leading independent equity research, and corporate access firm focused on small and mid-cap public companies is issuing a comprehensive report on Aeterna Zentaris Inc. (AEZS), a specialty biopharmaceutical company, engages in developing and commercializing pharmaceutical therapies for treating oncology, endocrinology, and women's health. In intra-day trading on October 31, 2018, Aeterna Zentaris is at $2.11 per share (+62.31%) in reaction to Strongbridge Biopharma's out-licensing deal with Novo Nordisk for U.S. and Canadian rights to the AEZS drug MACRILEN (macimorelin). Details of the Macrilen™ and the Novo Nordisk deal and analysts review here READ MORE.
CHARLESTON, S.C., Nov. 01, 2018 -- Aeterna Zentaris Inc. (NASDAQ:AEZS) (TSX: AEZS) announces that it was advised yesterday that Strongbridge BioPharma Plc has signed an.
NEW YORK, NY / ACCESSWIRE / November 1, 2018 / Aeterna Zentaris saw its shares climbing as Wall Street learned about Novo Nordisk and Strongbridge Biopharma’s deal where Aeterna Zentaris stands to capitalize. ...
CHARLESTON, S.C., Oct. 31, 2018 -- Aeterna Zentaris Inc. (NASDAQ:AEZS) (TSX: AEZS) will announce its third quarter 2018 financial and operating results after market close on.
CORAL GABLES, FL / ACCESSWIRE / October 31,2018 / Institutional investors' focus onhealthcare services has grown over the last several quarters. "Institutional investors have been learning from their experience and will likely be using those lessons as they inject hundreds of billions in capital into healthcare in the next five years. As these trends continue to foster investment, companies like Premier Health Group, Inc. (PHGRF) (PHGI.CN), Aeterna Zentaris Inc. (AEZS)(TSX:AEZS.TO) and Veracyte, Inc. (VCYT) could be positioned to capitalize on this growth.